Calidi Biotherapeutics appoints Andrew Jackson as CFO effective Oct 30, 2023

Calidi Biotherapeutics, Inc.

Base salary $430k, annual bonus up to 35% of base, 300k incentive stock options with one-year cliff and 4-year vesting.
Severance: 6 months' base salary if terminated without cause or resigns with good reason; 12 months after change of control.
Jackson has over 25 years corporate finance experience, raised over $300M in financings, previously CFO at Eterna Therapeutics and Ra Medical Systems.
Led Ra Medical's IPO and established public company processes, controls, and infrastructure.

item 1.01 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Andrew Jackson

Chief Financial Officer

CLDI · Calidi Biotherapeutics, Inc.

Effective: 2023-10-30
Filed: October 30, 2023, 7:59 PM ET

On October 27, 2023, the Board of Directors approved and ratified the appointment of Mr. Andrew Jackson as the Chief Financial Officer of the Company and the Compensation Committee approved and ratified the Employment Agreement with Mr. Andrew Jackson effective October 30, 2023 .

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Andrew Jackson was appointed as Chief Financial Officer at Calidi Biotherapeutics, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On October 27, 2023, the Board of Directors approved and ratified the appointment of Mr. Andrew Jackson as the Chief Financial Officer of the Company and the Compensation Committee approved and ratified the Employment Agreement with Mr. Andrew Jackson effective October 30, 2023 .

View on SEC.gov

Calidi Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-038596

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.